---
title: "Design Therapeutics begins Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type 1 patients"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291279515.md"
description: "Design Therapeutics has initiated patient dosing in a Phase 1 multiple-ascending dose trial for DT-818, targeting adults with myotonic dystrophy type 1. The study evaluates safety, tolerability, pharmacokinetics, and pharmacodynamic effects, with results expected in 2027. DT-818 aims to reduce transcription of the mutant DMPK allele, marking a key step toward establishing early clinical proof of concept."
datetime: "2026-06-30T12:04:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291279515.md)
  - [en](https://longbridge.com/en/news/291279515.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291279515.md)
generator: "portal-rs"
---

# Design Therapeutics begins Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type 1 patients

-   Design Therapeutics began dosing patients in a Phase 1 multiple-ascending dose trial of DT-818 in adults with myotonic dystrophy type-1. \* The study will assess safety, tolerability, pharmacokinetics, pharmacodynamic effects; results will be reported in 2027. \* DT-818 aims to reduce transcription of the mutant DMPK allele, targeting the disease’s underlying genetic driver. \* The start of patient dosing advances DT-818 into clinical testing, a key step toward establishing early clinical proof of concept. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Design Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300800PRIMZONEFULLFEED9754562) on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [DSGN.US](https://longbridge.com/en/quote/DSGN.US.md)

## Related News & Research

- [Design Therapeutics Q2 FY26 net loss widens to $20.2 million; R&D expenses rise to $16.4 million](https://longbridge.com/en/news/294690302.md)
- [MSCL: SAT-3247 shows early clinical promise for DMD, with strong safety, efficacy, and financial backing](https://longbridge.com/en/news/296385164.md)
- [Satellos Bioscience posts investor deck outlining SAT-3247 muscle-regeneration approach for Duchenne dystrophy](https://longbridge.com/en/news/296435378.md)
- [Dynatrace Buys Arize for $915M to Expand AI Observability Reach](https://longbridge.com/en/news/296536339.md)
- [Capricor shares skyrocket as FDA agrees to review new Duchenne drug data](https://longbridge.com/en/news/295920863.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**